Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S, Messori A
Department of Gynaecology and Obstetrics, Catholic University, Rome, Italy.
Br J Cancer. 1997;76(5):661-6. doi: 10.1038/bjc.1997.442.
Several reports have evaluated the correlation between cathepsin-D and overall survival or disease-free survival in node-negative breast cancer patients. Because conflicting data have so far been reported, a meta-analysis was conducted to clarify this problem. Eleven studies were included in our meta-analysis (total of 2690 patients). A specific meta-analytical methodology for censored data was used, and disease-free survival was the primary end point. Patients with low cathepsin-D levels had a significantly better disease-free survival than patients with high cathepsin-D values (meta-analytical odds ratio from 0.59 to 0.60 over the interval from 1 to 7 years). A secondary meta-analysis conducted exclusively on the data from eight studies based on cytosol assay gave substantially similar results. One limitation of our study is that the cut-off values to define high and low cathepsin-D concentrations were not identical in the various studies included in our meta-analysis (range from 20 to 78 pmol mg(-1) protein), thus introducing a possible bias in the statistical analysis of the data. However, a simulation based on the well-accepted method of the so-called publication bias showed that more than 100 null studies would be required to lead our results to a statistical level of non-significance. Considering the results of our meta-analysis, we conclude that the data presently available confirm a statistically significant association between high cathepsin-D values and poor disease-free survival in node-negative breast cancer patients.
已有多项报告评估了组织蛋白酶D与淋巴结阴性乳腺癌患者总生存期或无病生存期之间的相关性。由于目前已报告的数据相互矛盾,因此进行了一项荟萃分析以阐明这一问题。我们的荟萃分析纳入了11项研究(共2690例患者)。采用了针对删失数据的特定荟萃分析方法,无病生存期为主要终点。组织蛋白酶D水平低的患者无病生存期明显优于组织蛋白酶D值高的患者(1至7年期间的荟萃分析优势比为0.59至0.60)。仅对基于胞质溶胶测定的8项研究的数据进行的二次荟萃分析得出了基本相似的结果。我们研究的一个局限性在于,在我们荟萃分析纳入的各项研究中,用于定义组织蛋白酶D高浓度和低浓度的临界值并不相同(范围为20至78 pmol mg(-1)蛋白质),从而在数据的统计分析中引入了可能的偏差。然而,基于广为接受的所谓发表偏倚方法进行的模拟显示,需要超过100项阴性研究才能使我们的结果达到无统计学意义的水平。考虑到我们荟萃分析的结果,我们得出结论,目前可得的数据证实组织蛋白酶D值高与淋巴结阴性乳腺癌患者无病生存期差之间存在统计学上的显著关联。